Rigel Pharmaceuticals Inc
NASDAQ:RIGL

Watchlist Manager
Rigel Pharmaceuticals Inc Logo
Rigel Pharmaceuticals Inc
NASDAQ:RIGL
Watchlist
Price: 40.78 USD -3.02% Market Closed
Market Cap: 740.2m USD

EV/EBIT
Enterprise Value to EBIT

5.3
Current
-12.7
Median
7
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
5.3
=
Enterprise Value
632.7m USD
/
EBIT
119m USD
All Countries
Close
EBIT Growth EV/EBIT to Growth
US
Rigel Pharmaceuticals Inc
NASDAQ:RIGL
Average EV/EBIT: 41.3
5.3
77%
0.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 793.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.7
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.4
13%
1.4
AU
CSL Ltd
ASX:CSL
16.5
11%
1.5
NL
argenx SE
XBRU:ARGX
62.6
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
191.6
N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
hidden
2-Years Forward
EV/EBIT
hidden
3-Years Forward
EV/EBIT
hidden